Eisai heart drug may lower heart risks

Japanese drugmaker Eisai's blood clot candidate E5555 may be able to reduce heart attacks, strokes and cardiovascular deaths without increased serious bleeding risks, researchers say. Scientists evaluated E5555, a new protease-activated receptor 1 inhibitor, in two Phase II trials in Japanese patients to assess the drug's safety and tolerability. The researchers also wanted to determine its effects on major adverse cardiac events (MACE) and platelet aggregation in acute coronary...